Laurus Labs said its first commercial-scale peptide plant in Vizag is operational as the pharmaceutical maker reported first-half capital spending equal to 20% of revenue and approved an interim dividend.
The company said capital expenditure in the first half of FY27 was 20% of revenue. Separately, its six-month results filing recorded ₹864.19 crore in cash outflows for property, plant and equipment and related capital-work movements.
Laurus said it is expanding capacity and investing in oligonucleotides and peptide-resin technologies alongside the Vizag plant. The company attributed gross-margin expansion to a favorable business mix and said growth in commercial supplies improved capacity efficiency.
For the quarter ended Sept. 30, 2026, consolidated revenue from operations rose 33.4% to ₹2,206.37 crore from ₹1,653.47 crore a year earlier. Consolidated profit after tax increased to ₹436.74 crore from ₹193.75 crore. The filing separately listed ₹441.48 crore in profit attributable to the parent company’s equity holders, compared with ₹194.97 crore a year earlier. EconoTimes previously covered the quarter’s profit and margin results.
Laurus linked quarterly growth to higher contract development and manufacturing organization (CDMO) revenue and continued momentum in its Affordable Medicines division. Founder and CEO Dr. Satyanarayana Chava called it “another record quarter.”
The Economic Times reported that Laurus shares were up 3.79% at ₹2,329 at 1:01 a.m. EDT (05:01 UTC) Friday, Oct. 30.
The board approved an interim dividend of ₹1 per share with a ₹2 face value. The record date is Friday, Nov. 6, and payment is due on or after Nov. 19.
